Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ReposiTrak (TRAK) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for ReposiTrak (TRAK) over the last 16 years, with Q3 2025 value amounting to $28.8 million.

  • ReposiTrak's Cash & Equivalents rose 1165.02% to $28.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.8 million, marking a year-over-year increase of 1165.02%. This contributed to the annual value of $28.6 million for FY2025, which is 1357.62% up from last year.
  • As of Q3 2025, ReposiTrak's Cash & Equivalents stood at $28.8 million, which was up 1165.02% from $28.6 million recorded in Q2 2025.
  • In the past 5 years, ReposiTrak's Cash & Equivalents ranged from a high of $28.8 million in Q3 2025 and a low of $20.4 million during Q3 2021
  • Over the past 5 years, ReposiTrak's median Cash & Equivalents value was $23.7 million (recorded in 2023), while the average stood at $24.1 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first surged by 2959.44% in 2021, then crashed by 1084.06% in 2022.
  • Over the past 5 years, ReposiTrak's Cash & Equivalents (Quarter) stood at $21.7 million in 2021, then fell by 1.42% to $21.4 million in 2022, then increased by 8.66% to $23.3 million in 2023, then grew by 20.59% to $28.0 million in 2024, then increased by 2.69% to $28.8 million in 2025.
  • Its Cash & Equivalents was $28.8 million in Q3 2025, compared to $28.6 million in Q2 2025 and $28.1 million in Q1 2025.